TW201110995A - Oral composition for alleviation of ultraviolet radiation-induced damage - Google Patents
Oral composition for alleviation of ultraviolet radiation-induced damage Download PDFInfo
- Publication number
- TW201110995A TW201110995A TW099110035A TW99110035A TW201110995A TW 201110995 A TW201110995 A TW 201110995A TW 099110035 A TW099110035 A TW 099110035A TW 99110035 A TW99110035 A TW 99110035A TW 201110995 A TW201110995 A TW 201110995A
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- methionine
- disease
- skin
- ultraviolet
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 230000006378 damage Effects 0.000 title claims abstract description 33
- 230000005855 radiation Effects 0.000 title abstract description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 86
- 229930182817 methionine Natural products 0.000 claims abstract description 79
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- 208000002177 Cataract Diseases 0.000 claims abstract description 21
- 208000017520 skin disease Diseases 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 11
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 230000037303 wrinkles Effects 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 14
- 201000004624 Dermatitis Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 230000001684 chronic effect Effects 0.000 claims description 9
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 8
- 208000001126 Keratosis Diseases 0.000 claims description 8
- 201000008937 atopic dermatitis Diseases 0.000 claims description 8
- 208000010668 atopic eczema Diseases 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 206010013786 Dry skin Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 230000037336 dry skin Effects 0.000 claims description 5
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 208000019872 Drug Eruptions Diseases 0.000 claims description 4
- 206010015150 Erythema Diseases 0.000 claims description 4
- 231100000321 erythema Toxicity 0.000 claims description 4
- 208000002440 photoallergic dermatitis Diseases 0.000 claims description 4
- 230000003449 preventive effect Effects 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 3
- 208000012777 Hartnup Disease Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 230000000172 allergic effect Effects 0.000 claims description 3
- 201000011486 lichen planus Diseases 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 206010048768 Dermatosis Diseases 0.000 claims description 2
- 206010014970 Ephelides Diseases 0.000 claims description 2
- 208000003351 Melanosis Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 206010002091 Anaesthesia Diseases 0.000 claims 1
- 241000101040 Pityriasis Species 0.000 claims 1
- 230000037005 anaesthesia Effects 0.000 claims 1
- 238000001949 anaesthesia Methods 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 238000001126 phototherapy Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 230000001153 anti-wrinkle effect Effects 0.000 abstract 2
- 229960004452 methionine Drugs 0.000 description 81
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 30
- 238000000034 method Methods 0.000 description 29
- 229930182818 D-methionine Natural products 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 239000002609 medium Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 238000013329 compounding Methods 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 235000021419 vinegar Nutrition 0.000 description 11
- 239000000052 vinegar Substances 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- -1 2-ethylhexyl decyl cinnamate Chemical compound 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 235000013557 nattō Nutrition 0.000 description 8
- 235000013555 soy sauce Nutrition 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000013312 flour Nutrition 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000037373 wrinkle formation Effects 0.000 description 6
- 235000010469 Glycine max Nutrition 0.000 description 5
- 150000008575 L-amino acids Chemical class 0.000 description 5
- 240000008415 Lactuca sativa Species 0.000 description 5
- 240000007594 Oryza sativa Species 0.000 description 5
- 235000007164 Oryza sativa Nutrition 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000116 mitigating effect Effects 0.000 description 5
- 235000009566 rice Nutrition 0.000 description 5
- 235000012045 salad Nutrition 0.000 description 5
- 230000037380 skin damage Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 4
- 229930195722 L-methionine Natural products 0.000 description 4
- 244000294411 Mirabilis expansa Species 0.000 description 4
- 235000015429 Mirabilis expansa Nutrition 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 150000002741 methionine derivatives Chemical class 0.000 description 4
- 235000013536 miso Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 235000013599 spices Nutrition 0.000 description 4
- 235000002566 Capsicum Nutrition 0.000 description 3
- 150000008574 D-amino acids Chemical class 0.000 description 3
- 208000002506 Darier Disease Diseases 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010023369 Keratosis follicular Diseases 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- 229920000877 Melamine resin Polymers 0.000 description 3
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
- 208000002141 Pellagra Diseases 0.000 description 3
- 239000006002 Pepper Substances 0.000 description 3
- 235000016761 Piper aduncum Nutrition 0.000 description 3
- 240000003889 Piper guineense Species 0.000 description 3
- 235000017804 Piper guineense Nutrition 0.000 description 3
- 235000008184 Piper nigrum Nutrition 0.000 description 3
- 241000097929 Porphyria Species 0.000 description 3
- 208000010642 Porphyrias Diseases 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 235000015895 biscuits Nutrition 0.000 description 3
- 235000008429 bread Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 208000010247 contact dermatitis Diseases 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 235000011194 food seasoning agent Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 201000004607 keratosis follicularis Diseases 0.000 description 3
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 3
- 210000004560 pineal gland Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 229960002429 proline Drugs 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- BIXCZKNSCJNZBL-LXGUWJNJSA-N (2r,3r,4s,5r)-2-(ethylamino)-3,4,5,6-tetrahydroxyhexanal Chemical compound CCN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO BIXCZKNSCJNZBL-LXGUWJNJSA-N 0.000 description 2
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 208000013165 Bowen disease Diseases 0.000 description 2
- 208000019337 Bowen disease of the skin Diseases 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 2
- 229930195711 D-Serine Natural products 0.000 description 2
- 229930182820 D-proline Natural products 0.000 description 2
- 241000208688 Eucommia Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940008396 carrot extract Drugs 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000014510 cooky Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 238000002309 gasification Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 235000014438 salad dressings Nutrition 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 241000371652 Curvularia clavata Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000492333 Harpa Species 0.000 description 1
- 240000000455 Holodiscus discolor Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000010931 Mesua ferrea Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000005704 Olneya tesota Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 235000008198 Prosopis juliflora Nutrition 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000021420 balsamic vinegar Nutrition 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 229910001422 barium ion Inorganic materials 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 208000007287 cheilitis Diseases 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HBGGXOJOCNVPFY-UHFFFAOYSA-N diisononyl phthalate Chemical compound CC(C)CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC(C)C HBGGXOJOCNVPFY-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001955 polyphenylene ether Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000008525 senile cataract Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000012748 slip agent Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 125000005555 sulfoximide group Chemical group 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/24—Organic nitrogen compounds
- A21D2/245—Amino acids, nucleic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Birds (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
201110995 六、發明說明: 【發明所屬之技術領域】 本發明係有關一種紫外線傷害減輕之經口組合物,其含 有選自由蛋胺酸、與其衍生物及/或鹽所組成之群組的一 種或兩種以上之化合物;一種紫外線曝露所引起之皮膚疾 患及皮膚之美容狀態的改善方法,其包含投與蛋胺酸、與 其付生物及/或鹽之群組的一種或兩種以上之化合物之步 驟;以及一種包含投與上述化合物之步驟之白内障治療及/ 或預防方法。 【先前技術】 紫外線可分類為較約320 nm為長之長波長帶紫外線(uv_ A)、約320〜約280 nm之中波長帶紫外線(UV_B)、及較約 280 nm為短之短波長帶紫外線(UV-C)。其中,UV-C因可 由臭氧層吸收,不含於到達地面之太陽光中。UV_A不會 被臭氧層吸收,占到達地面之紫外線的大部分。又,uv_ B雖一部分可被臭氧層吸收,但以ϋν-Α之1000分之丨的光 ΐ即會造成皮膚傷害。因此’ UV_A& υν_ Β作為皮膚傷害 之主要原因均㈣重要。根據非專利文獻1,與紫外線有 關之疾病’可舉的有皺紋、紅斑、色素性乾皮症、慢性光 線性皮膚炎、扁平上皮癌、基底細胞癌、惡性黑色腫、波 文氏(Bowen)病、日光角化症’光線過敏症、接種癌狀水 癌症及光接觸皮膚炎;根據非專利文獻],與紫外線有關 之疾病’可舉的有曰光皮膚炎、慢性光線皮膚症、光線角 化症、光、線口唇炎、F_-R_Ch〇t病、光線過敏症、光 147I08.doc 201110995 接觸皮膚炎、伯洛克(berloque)皮膚炎、光線過敏性藥 疹、多形日光疹、接種痘狀水泡症、日光蓴麻療、慢性光 線過敏性皮膚炎、色素性乾皮症、雀即斑、紫質症 (porphyria)、糙皮病、胺基酸吸收障礙病、日光角化症、 皮膚筋炎、扁平苔癬、Darier病、毛孔性紅色粃糠疹、酒 糟狀皮膚炎、異位性皮膚炎、肝斑、單純性范療及紅斑性 狼瘡等等。 先行技術文獻 非專利文獻 非專利文獻1 :皮膚疾患最新之治療2〇〇5、v_ 非專利文獻2 :標準皮膚科學第7版(醫學書院) 【發明内容】 迄今之紫外線皮膚傷害之預防及/或治療劑,已有阻礙 紫外線之皮膚吸收的如氧化鈦般之紫外線散射劑或對曱氧 基肉桂酸2-乙基己酯般之紫外線吸收劑,或將紫外線所產 生之游離自由基除去之抗氧化劑,然而,紫外線散射劑' 紫外線吸收劑對於屋外之日曬有效,但非日常使用者。 又’抗氧化劑在安定性及安全性上有問題。再者對於紫 外線所造成之皮膚傷害的治療劑,只有對㈣㈣為人所 知。又,皮膚外用劑則有連續投與困難之問題。是以,有 必要開發出日常可使用、可經口攝取' 文疋且安全之紫外 線傷害減輕經口組合物、皺紋抑制劑、 叉價疾患治療用及/ = 方二醫藥品組合物、食品組合物、白内障預防或治療 用^樂〇口組合物。 147108.doc 201110995 本發明提供一種紫外線傷害減輕之經口組合物,其含有 選自由蛋胺酸、與其衍生物及/或鹽所組成之群組的一種 或兩種以上之化合物。 本發明之紫外線傷害減輕之經口組合物中,上述蛋胺酸 可為D-體。 上述紫外線傷害減輕之經口組合物可為皺紋抑制劑。 上述紫外線傷害減輕之經口組合物可作為皮膚疾患用醫 藥品使用。 上述皮膚疾患可選自由紅斑、曰光皮膚炎、慢性光線皮 膚症光線角化症、光線口唇炎、Favre-Racouchot病、光 線過敏症、光接觸皮膚炎、伯洛克(bedoque)皮膚炎、光 線過敏性藥疹、多形日光疹、接種痘狀水泡症、曰光蓴麻 療、慢性光線過敏性皮膚炎、色素性乾皮症、雀卵斑、紫 質症(porphyria)、糙皮病、Hartnup病、日光角化症、皮膚 筋炎、扁平苔癖、Darier病、毛孔性紅色粃糠疹、酒糟狀 皮膚炎、異位性皮膚炎、肝斑、單純性疱疹、紅斑性狼 ; 扁平上皮癌、基底細胞癌及波文氏(B〇wen)病所組成 之群組。 本發明紫外線傷害減輕之經口組合物中,上述皮膚疾患 用醫藥品可為皮膚疾患用治療劑。 本發明紫外線傷害減輕之經口組合物中,上14皮膚疾患 用醫藥品可為皮膚疾患用預防劑。 本發明紫外線傷害減輕之經口組合物,可用作為食品。 本發明紫外線傷害減輕之經σ組合物,可用作為白内障 147108.doc 201110995 用醫藥品。 本發明紫外線傷害減輕之經口組合物中,上述白内障用 醫藥品可為白内障用治療劑或白内障用預防劑。 上述白内障可為老人性白内障。 /本發明提供—種紫外線曝露所引起之皮膚疾患之治療及/ 或預防方法,其包含投與紫外線傷害減輕經口組合物之步 驟,,該紫外線傷害減輕經口組合物含有選自由蛋胺酸、與 其衍生物及/或鹽所組成之群組的一種或兩種以上之化合 物。上述皮膚疾患可選自由紅斑、日光皮膚炎' 慢性光線 皮膚症、光線角化症、光線口唇炎、Favre Rac〇uch〇t病、 光線過敏症、光接觸皮膚炎、伯洛克(berl〇que)皮膚炎、 光線過敏性藥疹、多形日光疹、接種痘狀水泡症、日光蓴 麻疹、慢性光線過敏性皮膚炎、色素性乾皮症、雀印斑、 务質症(porphyria)、糙皮病、Hartnup病、曰光角化症 '皮 膚肋扁平台癬、Darier病、毛孔性紅色粃糠療、酒糟 狀皮膚炎、異位性皮膚炎、肝斑、單純性疱疹、紅斑性狼 瘡扁平上皮癌、基底細胞癌及波文氏(Bowen)病所組成 之群組。上述蛋胺酸可為D-體。 本發明提供一種皮膚美容狀態之改善方法,其包含投與 紫外線傷害減輕經口組合物之步驟,該紫外線傷害減輕經 口組合物含有選自由蛋胺酸、與其衍生物及/或鹽所組成 之群組的一種或兩種以上之化合物。上述皮膚美容狀態之 改善方法中,含有選自由蛋胺酸、與其衍生物及/或鹽所 組成之群組的一種或兩種以上之化合物的紫外線傷害減輕 147108.doc 201110995 經食品組合物。上 善可為皺2ΓΓβ^#方法卜μ美容狀《之改 、又抑制,但不受此限制。 本叙明提供—種白内障之治 投與-種组合物之步驟八物5彳其包含 妒彻甘 a,,且&物含有選自由L-及D-蛋胺 酉文與其衍生物及/或鹽所έ 之化合物。 成之群組的-種或兩種以上 :::之白内障治療及/或預防方法I上
為老人性白内障。 + J 本說明書中,番_胳西參夕「 麗」,係指以無損蛋胺酸之紫 =傷。之減輕效果為條件’包含金屬鹽、胺鹽等之任何 之现。上述金屬鹽可包含驗金屬鹽,驗土類金屬鹽等。上 述胺鹽可包含三乙胺鹽、苄胺鹽等。 =明書中’蛋胺酸之「衍生物」,係指以無損蛋胺酸 之表外線傷害的減輕效果為條件,蛋胺酸分子在其胺基、 缓基或側鏈中’與任何原子團共價結合而成者。上述任何 原子團,包含N_苯基乙酿基、4,4,•二甲氧基三苯曱(dmt) 基4般之保護基’蛋白質、狀、糖、脂質'核酸等般之生 體:分子’聚苯乙稀、聚乙稀、聚乙烯系、聚醋等般之合 成冋刀子’酯基等般之官能基’但不限於此。上述酯基, 可I 3例如曱自曰、乙酯或其他之脂族酯,或是芳族酯。 胺基酸,作為其光學異構物包括L·體與D-體,天然之蛋 白質係L-胺基酸作胜肽結合而成者’除去細菌之細胞壁等 之例外’只有L-胺基酸被利用,因此咸信以人類為首之哺 147108.doc 201110995 礼類中只有L-胺基酸存在,且只有利用L_胺基酸(木野内 忠稳4人’蛋白質核酸酵素’ 5〇 : 453-460 (2005),雷寧 加之新生化學[上]第2版卯132 147 (1993)廣川書店哈帕 •生化學原書22版pp 21-30(1991)丸善)。因此,迄今為 止,不管是學術上或産業上,作為胺基酸只有^胺基酸被 使用至今。 例外地,D-胺基酸有使用的實例情況是,作為細菌産生 之抗生物質的原料使用之情況,以及為節約自化學合成胺 基時專里獲彳于之L-胺基酸與D-胺基酸混合物只分取胺 基I之成本,而原狀以DL-胺基酸混合物之形態使用胺 基酸之食品添加物之情況。然而,作為具有生理活性之物 質,產業上只使用D-胺基酸的例子迄今還付之闕如。 D-絲胺酸或D-天(門)冬胺酸因1)_體之比率高,故其研究 較為盛行。D-絲胺酸局部存在於大腦、海馬體中,作為腦 内之NMDA受體之調節因子已為人所明瞭。〇_天(門)冬胺 酸被認為局部存在於精巢或松果體,與荷爾蒙分泌之控制 有關(特開2005-3558号公報广然而,對於皮膚,特別是紫 外線傷害之L-及D-蛋胺酸之生理作用尚未明朗。 如以下實施例所示,L-體或D_體、或其混合物之蛋胺 酸,其紫外線傷害之減輕效果迄今為止聞所未聞。因此, 本發明之含L-及/或D-蛋胺酸之紫外線傷害減輕經口組合 物係新穎發明。 近年已被報告的是,令ddY小鼠在2週内自由攝取1〇 mM 之D-胺基酸水溶液後’針對各器官測“·胺基酸濃度時發 U7108.doc 201110995 現,松果體中相對松果體!腺為3·1〇〇〇 —,腦組織 對濕重量 1 g 為 2-500 nm〇i(M〇rikawa,A 等人,Amin〇 Acids’ 32 · 13·20 (2007))。基於此’算出以下說明之本發 明組口物中所含之L·及D-蛋胺酸的一日攝取量的下限。 本發明之蛋胺酸,如以下之實施例所示,相對培養人類 纖維芽細胞以0.001〜100 -,對小鼠以1〇 _之濃度具有 紫外線傷害減輕之效果。因此,本發明之醫藥品組合物、 敏紋抑制劑及食品組合物中所含之蛋胺酸之量,以此濃度 範圍之=胺酸可送達生體皮膚組織之纖維芽細胞為條件, 何3里均可本發明組合物為内服劑時之蛋胺酸之含 量’只要是〇.〇_01重量%〜1〇〇重量%均可。本發明組合 物為内服劑時之蛋胺酸之含量,宜為0 00咖2重量%〜80重 量%,最好為〇._02重量%〜60重量%。又,本發明組合物 中所含之队蛋胺酸之1攝取量之下限,相對體重! kg為 〇·01叫即可,宜為0.1 ng,更好是1 ng。本發明組成物中 戶:3之L-蛋胺酸的一曰攝取量之下限,係較臨床藥之投與 量(體重1 kg為2 mg以上)為少之量,體重ι ^為qgi叫即 可’宜為0.1 mg,更好的是1 mg。 發月之組口物,除蛋胺酸之翠體、蛋胺酸之鹽及/或 生體内可藉藥物代謝酵素或其他因素放出蛋胺酸之衍生 物以外’以無損蛋胺酸之抗氧化傷害之效果為條件,進而 可包含-種或兩種以上之藥學可容許之添加物。上述添加 ’包含稀釋劑及膨脹劑、結合劑及接著劑 '滑劑及流動 進^、可塑劑、朋解劑、載體溶媒、緩衝劑、著色料、 ;’:甘未料防腐劑及安定劑、吸附劑、業者所知之其 147I08.doc 201110995 他醫藥品添加劑,但不受此限制。 本發明之皺紋抑制劑,作為其有效成分,可僅使用蛋胺 酸、蛋胺酸之鹽及/或生體内可藉藥物代謝酵素或其他因 素放出蛋胺酸酸之料物調製,但—般在無損本發明效果 的範圍内’可因應必要適當混合含緩效藥品之化妝品或醫 藥品等之皮膚外用劑等中所用之其他成分。作為上述其他 成分(任意展合成分),例如可舉的有油分、界面活性劑、 粉末、色材、水、醇類、增黏劑、f合劑、㈣類、抗氧 i 匕劑、紫外線吸收劑、保濕劑、香料、各種藥效成分、防 腐劑、pH調整劑 '中和劑等等。 本發明之食品組合物’除蛋胺酸、蛋胺酸之鹽及/或生 體内可藉藥物代謝酵素或其他因素放出蛋胺酸之衍生物, 以無損蛋胺酸之紫外線傷害之減輕效果為條件,可含有, 味料、著色料、保存料或其他作為食品可容許之成分。 本發明之食二組合物,例如可為清涼飲料、果束、糖 果錠狀餅乾寻,先前食品組合物所採用者均可不受上 述例示之限定。 /外線曝露據信不只是皮膚疾患,對於眼睛疾患,特別 1内_一個原因。據知小鼠若長期曝露於紫外線,則 水:體之刖部皮質會產生白;蜀’實驗上可製作白内障模型 U里多佳美及岩㈣造’「水晶體之生化學機構」,川_ ⑵頁,岩田修造編,MEDICAL蔡出版,東京⑽6))。 又’咸信老人性白内障原因之一是紫外線(藤永豐 障眼科M00KN。.17」,頁,三島濟-等人編著,金原 147108.doc 201110995 出版’東京(1982)),Zigman等人,根據馬尼拉、灘帕及羅 徹斯特之疫學調査,表示紫外線之照射量與白内障之發生 率相關,紫外線係白内障之危險因子(Zigman,S.等人,
Invest. Ophthalmol. Visual Sci. 18:462-467 (1979))。因 此’根據以上之知識及見解、以及以下之實施例,可知具 有务、外線傷害減輕效果之L-及D-蛋胺酸,對於白内障之預 防或治療有效。 【實施方式】 以下說明之本發明之實施例僅為例示之目的,並未限定 本發明之技術範圍。本發明之技術範圍僅由申請專利範圍 之記載所限定。 以下之研討’係根據美國國立衛生研究所(National Institutes of Health (NIH))之指導方針,由資生堂研究中心 之倫理委員會承認後實施。 實施例1 使用培養細胞之紫外線傷害試驗 紫外線照射及蛋胺酸添加之方法 細胞係使用市售之人類新生兒真皮纖維芽細胞(Cry〇 NHDF Neo —光純藥)。將細胞以2χ 105個之方式接種於 市售35 mm徑之培養組織(BD FALCON 353001,曰本 Becton’ Dickinson)中’而採用在市售之細胞培養用培養基 (D-MEM(1 g/L葡萄糖),和光純藥)添加有胎牛血清應、 抗生物質(15240-062,GIBC〇)1%之培養基(以下稱「一般 培養基」)進行培養。將上述細胞在37〇c下於5% 及飽 147I08.doc 201110995 和水蒸氣氛圍下作約24小時培養。 而後’將上述培養細胞之培養基’切換成添加有谷胱甘 肽之生物合成阻礙劑 BSO(L-bUthi〇nine-(S,R)_sulfoximine, 和光純藥)1χ10-3%之BSO培養基1 mL,在37°C、5% (:02及 飽和水蒸氣氛圍下作約24小時培養。上述BS0培養基係將 0.2% BSO溶於乙醇而成之保存用原液在上述一般培養基中 稀釋成200倍而調製。 紫外線照射前之蛋胺酸添加 紫外線照射前之蛋胺酸添加(以下稱為「照射前添加」) 之效果 研討時,係在照射24小時前切換成添加有〇 〇〇1〜1〇〇 μΜ 之L-或D-蛋胺酸之BSO培養基。將切換成添加有〇ι ^河之 D-脯胺酸之培養基後的紫外線照射作為陽性對照,將未添 加有此等胺基酸之原狀培養基的紫外線照射作為陰性對 昭 〇 紫外線照射用培養基 氣化鐵⑻於蒸顧水以成為2χ1〇-3%之方式溶解,將溶解 液以稀釋成200倍(終濃度1χ1〇-5%)之方式以含弼離子鎂 離子之磷酸緩衝生理食鹽水PBs(+)稀釋而製作之培養美 (以下稱為「紫外線照射用培養基」)預加溫成抓使用。 紫外線照射 UV- A照射前,將培養基詈拖占 丞直換成上述紫外線照射用培養 基1 mL。UV-A照射係、使用紫夕卜光均一曝光裝置魏_ 則亂16G(三永電機製作所),在除去培養組織之蓋之 147108.doc *12· 201110995
狀態下’自該培養組織之約20 cm上部,照射320 nm〜4〇〇 nm之紫外線8或9 J/cm2而實施。紫外線量係使用UV RADIOMETER UVR-3036/S(株式會社 TOPCON)測定。 紫外線照射後之蛋胺酸添加 紫外線照射後’恢復到上述一般培養基,作4〇小時、37 °C下5% C〇2及飽和水蒸氣氛圍下之培養。紫外線照射後之 蛋胺酸添加(以下稱為「照射後添加」)之效果研討時,係 在此40小時培養之培養基中添加〇 〇〇1〜1〇〇 之L-或D-蛋 胺酸。 照射前添加及照射後添加時之細胞傷害之定量 而後’在培養基中以最終濃度為i 〇%之方式添加 alamarBlue(商標 Invitrogen),3小時後,依據 Ahmed S. A. %人(J. Immunol. Method. 1 70,2 11-224 (1994))及製造者 之指示書以激勵波長544 nm ’螢光波長590 nm測定上清液 之螢光強度。 照射刖添加的結果 圖1顯示對於UV-A 9 J/cm2紫外線照射所造成之纖維芽細 胞之傷害’調查L-或D-蛋胺酸之照射前添加之效果的實驗 結果。各貫驗條件之誤差棒係表示以同一條件重複4次之 貫驗結果的測定值之標準偏差。又,星型記號(*)係表示 Bonferroni/Dunn檢定下p未達5%,星型記號(**)係表示 Bonferroni/Dunn檢定下p未達1%,星型記號(***)係表示 Bonferroni/Dunn檢定下 p未達 〇, 1%。 UV-A 9 J/cm2照射前胺基酸未添加時(陰性對照)之活細 147108.doc -13- 201110995 胞率為24%» ^ 脯胺酸照射前添加時(陽性對照) 之活細胞率為100%,細胞傷害獲得減輕。0.01 μΜ、〇 i μΜ、1 μΜ、l〇 pMa100 μΜ之D_蛋胺酸照射前添加時之 活細胞率,分別為102%、81%、97%、114%或76%。〇 〇〇1 μΜ、〇·〇1 μΜ、〇1 μΜ、丨 μΜ、1〇 _或1〇〇 _之^蛋胺 酸照射前添加時之活細胞率分別為4〇%、72%、67%、 45%、73%或62。/。。由以上結果可知,若添加^或〇蛋胺 酸活細胞率増大,細胞死亡獲得減輕。 照射後添加之結果 圖2顯示對於UV-A 8 J/cm2紫外線照射所造成之纖維芽細 胞之傷害,調查D-蛋胺酸之照射後添加之效果的實驗結 果。各貫驗條件之块差棒係表示以同—條件重複4次之實 驗結果的測定值之標準偏差。又,星型記號(***)係表示 Bonferroni/Dunn檢定下 p未達 0.1%。 UV-A 8 J/cm2照射後胺基酸未添加時(陰性對照)之活細 胞率為64%。0.1 μΜ之D-脯胺酸添加時(陽性對照)之活細 胞率增大至82。/。,細胞死亡獲得減輕^ 〇 〇ι μΜ、〇」μΜ、 1 μΜ、10 μΜ或100 μΜ之D-蛋胺酸照射後添加時之活細胞 率分別為93%、84%、82%、81%或87%。由以上結果可 知’若添加D-蛋胺酸,活細胞率增大,細胞死亡獲得減 輕。細胞死亡之減輕效果,顯然和D·蛋胺酸添加是在紫外 線照射之刖後無關。又’ L-蛋胺酸亦會減輕紫外線照射所 造成之細胞死亡。因此,此表示與L-蛋胺酸在紫外線照射 前後添加無關。 147108.doc 14 201110995 實施例2 .使用無毛小鼠之紫外線傷害所造成之皱紋的生成抑制試 驗(1) • 紫外線照射及D-蛋胺酸投與之方法 • 使用雄性無毛小鼠(Hos:HR-l,6週齢,星野實驗動 物)’根據舒瓦魯茲等人之方法(Haratake a et al. j
Invest. Dermatol. 108:769-775, 1997.)部份變更而重複照射 UV-Bi*&(NaganumaM.etal.J.Dermatol.Sci.25:29-35,2001. Schwartz E. J. Invest. Dermatol. 91:158-161 1988) ’而形成皺紋。具體言之,在此小鼠背部每週3次, 在I2週内照射UV_B(光源;東芝ELECTRIC製東芝FL-20 SE 營光燈)。開始後之照射量為36 mJ/cm2/次,第2週以降徐 徐增加’第12週為216 mJ/cm2/次。總照射量為4 482 J/cm 。紫外線量係採用以UV RADIOMETER(UVR_ 305/365D (II),TOPCON)測定之値。又,UV_B照射期間 中,10 mM之D-蛋胺酸係以給水瓿投與。作為對照,飲料 水係以相同之方法投與。給水瓶係1週更換1次。 紫外線傷害所造成之肥厚皮膚之測定方法 紫外線照射終了後,將皮膚厚以厚度計(Mitsut〇y〇 ' CorPoration,PK-1012SU)測定。皮膚厚之測定値,係以厚 度計夾著皮膚而測定,因此記載成「皮膚厚χ2」。 皺紋生成之判定方法 對於小鼠之上述紫外線照射終了後,拍攝小鼠背部之照 片’以Bissett等人之方法(Bissett dl. et al. Photochemistry 147108.doc 201110995 and Photobiology 46:367-378,1987)變更一部分之方法,根 據下述表1所示之判定基準評價皺紋生成之程度。皺紋之 評價作業係由4名測定者個別進行,其後依合議制,就皺 紋生成之程度決定評分(以下簡稱為「評分」)。 皮膚厚之測定結果 圖3顯示對於總照射量4.482 J/cm2之UV-B照射所造成之 皮膚肥厚,調查D-蛋胺酸之效果的實驗結果。各實驗條件 之誤差棒係表示以同一條件重複6-7次之實驗結果的測定 值之標準偏差。又,星型記號(**)係表示Bonferroni/Dunn 檢定下p未達1 %,星型記號(* * *)係表示Bonferroni/Dunn檢 定下p未達0.1°/。。UV-B照射後之皮膚厚之測定値,UV-B未 照射且D-蛋胺酸未投與群(UV(-)/H20)為0.81 mm,UV-B照 射且D-蛋胺酸未投與群(UV(+)/H20)為1.25 mm,且UV-B 照射且D-蛋胺酸投與群組(UV(+)/D-Met)為1.00。由以上結 果可知,UV- B照射所造成之紫外線傷害會引起皮膚顯著 之肥厚,D-蛋胺酸顯示可將此皮膚之肥厚作統計學上有意 義之減輕。 [表1] 評分 '判定基準 0 無皺紋。 1 較評分2為淺、短,或數目少。 2 淺皺紋。 3 較評分2為深或長。較評分4為淺、短,或數目少。 4 全面為淺皺紋。 5 較評分4為深或長。較評分6為淺或短。 6 深長之敵紋。 7 較評分6既深且長之皺紋增加。較評分8為淺或短。 8 全面為深長之皺紋。 147108.doc -16- 201110995 皺紋形成之評價結果 圖4顯示對於總照射量1482 J/cm2之UV-Β照射所造成之 敵紋’調查D-蛋胺酸之效果之實驗結果。各實驗條件之誤 差棒係表示以同一條件重複6或7次之實驗結果的測定值之 標準偏差。又,星型記號(*)係表示Mann_Whitney之檢定 下P為1.8%。有關UV-B照射後之各評分之個體數,有關 UV-B未照射且D-蛋胺酸未投與群(uv(_)基準組),評分1為 6隻。有關UV- B照射且D-蛋胺酸未投與群⑴v(+)基準組) 之各評分的個體數,評分4為2隻,評分5為2隻,評分6為i 隻,評分7為1隻。有關UV_B照射且d—蛋胺酸投與群組 (UV(+)D-Met)之各評分的個體數,評分3為4隻,評分4為2 隻及汗分5為1隻。由以上結果可知,因UV_B照射所造成 之紫外線傷害,皺紋形成顯著増大,但是D_蛋胺酸顯示可 將此皺紋形成作統計學上有意義之減輕。 實施例3 使用無毛小鼠之紫外線傷精造成之皺紋生成的抑制試 驗(2) 方法 UV-B照射期間中’將10 mM之一或匕蛋胺酸以給水瓶 投與。紫外線照射及敏紋生成之判定,係以實施例2所説 明之方法進行。 結果 圖^顯示對於以實施例2之量的1;%3照射所造成之皺 紋,調查L-及D-蛋胺酸之效果的實驗結果。各實驗條件之 I47108.doc 201110995 誤差棒係表示以同一條件重複6〜7次之實驗結果的測定值 之標準偏差》又’星型記號(*)係表示Mann_Whitney之檢 定下p為0.55%。 UV-B照射後各評分之個體數,有關uv_b未照射且D-蛋 胺酸未投與群(uv(-)基準組),評分2為6隻。有關UVB照射 且D-蛋胺酸未投與群(uv(+)基準組)之各評分的個體數, 評分5為1隻’評分6為2隻,評分7為2隻且評分8為3隻《有 關UV-B照射且D-蛋胺酸投與群組(UV(+)D_Met)之各評分 的個體數,評分5為6隻且評分6為2隻。有關UV-B照射且L-蛋胺酸投與群(UV(+)L-Met)之各評分的個體數,評分4為1 隻,評分5為2隻,評分6為2隻且評分7為2隻。由以上結果 可知,因UV-B照射所造成之紫外線傷害,皺紋形成顯著 增大’但D-蛋胺酸顯示可將此皺紋形成作統計學上有意義 之減輕。L-蛋胺酸係如實施例1所示般之可減輕uV_a照 射所造成之細胞死亡,但亦顯示UV-B照射所造成之赦紋 形成無法如D-蛋胺酸程度般之減輕。 基於本發明’含蛋胺酸之錠劑、軟膠囊、顆粒、飲料、 糖果、餅乾、味噌、法國汁、沙拉醬、法國麵包、醬油、 洗頭、優格、調味料.納豆調味醬、納豆、甍底黑醋之混 配例係如下所示。以下之混配例中之蛋胺酸係〇_體及/或 L-體。此等混合例僅為例示目的而列舉,並無限制本發明 技術範圍之意圖。 147108.doc -18- 201110995 混配例ι(鍵劑) (組合物) 混配量(mg/1旋中) 蛋胺酸 360.5 乳糖 102.4 羧曱基纖維素鈉 29.9 羥丙基纖維素 6.8 硬脂酸鎂 5.2 結晶纖維素 10.2 515.0 混配例2(鍵劑) (組合物) 混配量(mg/1銳中) 蔗糖酯 70 結晶纖維素 74 曱基纖維素 36 甘油 25 蛋胺酸 475 N-乙醯基葡萄糖胺 200 玻璃酸 150 維他命E 30 維他命b6 20 維他命B2 10 α-硫辛酸 20 輔酶Q10 40 神經醯胺(筠篛抽出物) 50 L-脯胺酸 300 •19- 147108.doc 1500 201110995 混配例3(軟膠囊) (組合物) 混配量(mg/1膠囊中) 食用大豆油 530 杜仲抽出物 50 胡蘿蔔抽出物 50 蛋胺酸 100 蜂王乳 50 太平洋鐵木 30 GABA 30 蜜堪 60 明膠 375 甘油 120 甘油脂肪酸酯 105 1500 混配例4(軟膠囊) (組合物) 混配量(mg/1膠囊中) 玄米胚芽油 659 蛋胺酸 500 白藜蘆醇 1 蓮子胚芽抽出物 100 彈力蛋白 180 DNA 30 棻酸 30 1500 混配例5(顆粒) (組合物) 混配量(mg/1包中) 蛋胺酸 400 維他命C 100 大豆 isohurabon 250 還原乳糖 300 大豆寡糖 36 季戊四醇 36 糊精 30 香料 24 槔檬酸 24 147108.doc -20- 1200 201110995 混配例6(飲料) (組合物) 混配量(g/60 ml中) 杜仲抽出物 1.6 胡蘿蔔抽出物 1.6 蛋胺酸 1.6 還原麥芽糖水餘 28 季戊四醇 8 檸檬酸 2 香料 1.3 N-乙醯基葡萄糖胺 1 玻璃酸鈉 0.5 維他命E 0.3 維他命b6 0.2 維他命b2 0.1 α-硫辛酸 0.2 輔酶Q10 1.2 神經醯胺(筠篛抽出物) 0.4 L-脯胺酸 2 純水 其餘 60 混配例7(糖果) (組合物) 混配量(重量%) 砂糖 50 水# 48 蛋胺酸 1 香料 1 -21 · 147108.doc 100 201110995 混配例8(餅乾) (組合物) 混配量(重量%) 低筋麵粉 45 牛油 17.5 細砂糖 20.0 蛋胺酸 4.0 雞蛋 12.5 香料 1.0 100.0 混配例8(餅乾)之製造方法 在將牛油搜拌下,徐徐加入細砂糖,再添加雞蛋、蛋胺 酸及香料並搜拌之。在充分混合後,加入均一搖晃之低筋 麵粉並低速攪拌,以塊狀在冰箱内靜置。而後,予以成 型,在1 70°C下燒烤15分鐘,形成餅乾。 混配例9(味噌) (組合物) 混配量(g) 大豆 1000 米麴 1000 鹽 420 蛋胺酸 158 水 其餘 4000 混配例9(味噌)之製造方法 將米麴與鹽充分混合。另將洗淨之大豆,浸於3倍量之 水中一夜後將水遞除,一面加入新的水一面烹煮之,再移 置於竹籃。收集煮汁(種水),將蛋胺酸以成為1 0% w/v之 方式溶解之。之後,將煮好的大豆立即磨碎,並加入混有 鹽的米麴,一面將溶有上述蛋胺酸之種水加入,一面至成 147108.doc •22· 201110995 為黏土程度之硬度為止均一地予以⑨♦。將揉成湯團狀之 物確實地以無間隙之方式塞入桶之各個角落,使其表面平 坦化並以保鮮膜覆蓋密封。3個月後更換容器,使其表面 平坦化並以保鮮膜覆蓋。又,代替將蛋胺酸添加於種水, 也可使用多量產生蛋胺酸之米麴。為獲得上述米麴,可根 據日本特(開)20()8损558號中所記載之方法將蛋胺酸定量 而選出。又,也可在市售之味噌中加入蛋胺酸或其鹽。 混配例10(法國汁) (組合物) 混配量(重量%) 沙拉油 27.0 醋 30.0 氣化鈉 0.9 蛋胺酸 1.1 胡椒 1.0 60.0 混配例10(法國汁)之製造方法 在醋中添加氯化鈉及蛋胺酸之後,充分搜拌溶解。再加 入沙拉油,充分攪拌之 ’再加入胡椒 混配例11(沙拉醬) (組合物) 混配量(重量%) 沙拉油 134.0 醋 5 氯化鈉 0.9 蛋胺酸 1 蛋黃 18 砂糖 0.2 胡拖L 0.9 160.0 147108.doc 23· 201110995 混配例11(沙拉醬)之製造方法 在蛋κ (至溫)中加入醋、氣化鈉、蛋胺酸及胡椒之後, 以起泡器充分攪拌。再―點—點地加入沙拉油,持續授拌 乳化。最後’再加入砂糖授掉。 混配例12(法國麵包) (組合物) 尚筋麵粉 低筋麵粉 氣化鈉 砂糖 蛋胺酸 乾酵母 溫執_ 混配量(g) 140 60 6 2 4 128 混配例12 (法國麵包)之製造方法 >在溫熱水中加人砂糖1g及乾酵母進行預備發酵。再 高筋麵粉、低筋麵粉、氣化鈉、砂糖5 g及蛋胺酸置入 碗中’在其中置人預發酵之酵母。充分捏和後,予以形 為球形,以30°C作一次發酵。將捏和成之材料再次捏和 令其熟成後予以整形成適當形狀’再用電子發酵機做二 發酵。之後再形成花樣’在22〇t之電爐中烘焙3〇分鐘。 混配例15(醬油) (組合物) 市售醬油 蛋胺酸_ 混配量(g) 980 __20 1000 混配例13(醬油)之製造方法 147108.doc -24· 201110995 在市售之醬油中添加蛋胺酸充分攪拌。又,代替加入蛋 胺酸或其鹽,也可使用多量產生蛋胺酸之麴釀造醬油。為 獲得上述麴,可根據日本特(開)2008-185558號中所記載之 方法將蛋胺酸定量而選出。又,也可在市售之醬油中加入 蛋胺酸或其鹽。 混配例14(優格) (組合物) 混配量(g) 牛乳 880 保加利亞乳酸菌 50 嗜熱鏈球菌 50 香胺酸_20 1000 混配例14(優格)之製造方法 以40°C〜45°C令其發酵。也可使用其他之市售種菌,也 可在市售之優格中加入蛋胺酸。又,代替加入蛋胺酸或其 鹽,也可使用多量產生蛋胺酸之菌。為獲得上述菌,可根 據曰本特(開)2008-1 85558號中所記載之方法將蛋胺酸定量 而選出。又,也可在市售之優格中加入蛋胺酸或其鹽。 混配例15(澆頭) (組合物) 混配量(g) 蛋胺酸 50 海苔 15 L-谷胺酸鈉 10 氣化納 2 炒製芝麻 10 鯖魚片段 10 砂糖 1 醬油 2 147108.doc •25- 100 201110995 混?例2調味料,納豆調味醬) 市售之納豆調味醬 蚤胺酸 混配量(g) 9 1 10 混配例17(納豆) (組合物) 混配量(g) 市售之納豆 19.9 蛋胺酸 0.1 20 混配例17(納豆)之製造方法 代替加入蛋胺酸或其鹽,可使用多量產生蛋胺酸之菌製 作納旦。為獲得上述菌,可根據日本特(開85558號 中所δ己載之方法將蛋胺酸定量而選出。又,也可在市售之 納豆中加入蛋胺酸或其鹽。 混配例18(甕底黑醋) (組合物) 混配量(g) 市售之甕底黑醋 900 ____100 1000 混配例1 8(甕底黑醋)之製造方法 代替加入蛋胺酸或其鹽,也可使用多量產生蛋胺酸之 菌’製造醋、黑醋、甕底物。為獲得上述菌,可根據曰本 特(開)2008-185558號中所記載之方法將蛋胺酸定量而選 出°又,也可在市售之甕底黑醋中加入蛋胺酸或其鹽。 【圖式簡單說明】 圖1係對於正常人類真皮纖維芽細胞紫外線照射前,L_ 147108.doc •26- 201110995 或D-蛋胺酸添加的效果之棒狀圖; 圖2係對於正常人類真皮纖維芽細胞紫外線照射後,D_ 蛋胺酸添加的效果之棒狀圖; • 圖3係對於紫外線照射小鼠之皮膚厚增加,D-蛋胺酸投 - 與的效果之棒狀圖; 圖4係對於紫外線照射小鼠之皺紋形成,队蛋胺酸投與 的效果之標繪圖;及 圖5係對於紫外線照射小鼠之皺紋形成,乙、或蛋胺酸 投與的效果之標繪圖。 欠 I47108.doc •27·
Claims (1)
- 201110995 七、申請專利範圍: 1. 種表外線傷害減輕之經口組合物,其特徵為:含有選 自由蛋胺酸、與其衍生物及/或鹽所組成之群組的一種或 兩種以上之化合物。 2. 如請求項1之組合物,其中該蛋胺酸為D體。 3. 如請求項1或2之組合物’其係皺紋抑制劑。 4. 如請求項1至3中任一項之組合物,其係作為皮膚疾患用 '^樂品使用D 5.如請求項4之組合物,其卡該皮膚疾患係選自由紅斑、 光皮膚k、慢性光線皮膚症、光線角化症、光線口唇 炎、FaVre-Racouchot病、光線過敏症、光接觸皮膚炎、 伯洛克(berloque)皮膚炎、光線過敏性藥疹、多形曰光 療、接難狀水泡症、日光葬麻療、慢性光線過敏性皮 膚炎、色素性乾皮症、雀卵斑、紫f症(?。咖叫、縫 皮病、Hartnup病、日光角化症、皮膚筋炎、扁平苔癖、 Daner病、毛孔性紅色粃糠疹、酒糟狀皮膚炎、異位性 皮膚炎、肝斑、單純性癌療、紅斑性狼瘡、扁平上皮 癌:基底細胞癌及波文氏(BQWen)病所組成之群組。 6.:凊求項4或5之組合物,其中該皮膚疾患用醫藥品係皮 膚疾患用治療劑。 其中該皮膚疾患用醫藥品係皮 如請求項4或5之組合物, 膚疾患用預防劑。 8. 如請求項1或2之組合物, 9. 如請求項1或2之組合物 其係作為食品使用。 ,其係作為白内障用醫藥品使 147108.doc 201110995 用。 10.如請求項9之組合物 用治療劑或白内障用 ,其中該白内障用醫藥品係白内障 預防劑。 147108.doc
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009228267 | 2009-09-30 | ||
PCT/JP2010/055841 WO2011040070A1 (ja) | 2009-09-30 | 2010-03-31 | 紫外線障害軽減経口組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201110995A true TW201110995A (en) | 2011-04-01 |
Family
ID=43825907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW099110035A TW201110995A (en) | 2009-09-30 | 2010-03-31 | Oral composition for alleviation of ultraviolet radiation-induced damage |
Country Status (7)
Country | Link |
---|---|
US (1) | US20120189563A1 (zh) |
EP (1) | EP2484353A4 (zh) |
JP (1) | JP5703228B2 (zh) |
KR (1) | KR20120044993A (zh) |
CN (1) | CN102481277A (zh) |
TW (1) | TW201110995A (zh) |
WO (1) | WO2011040070A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120041740A (ko) * | 2009-09-14 | 2012-05-02 | 가부시키가이샤 시세이도 | 자외선 장해 경감 조성물 |
JP2012077022A (ja) * | 2010-09-30 | 2012-04-19 | Shiseido Co Ltd | Il−8発現抑制組成物 |
JP2013177356A (ja) * | 2012-02-29 | 2013-09-09 | Shiseido Co Ltd | 紫外線曝露によって促進される血管新生を抑制するための組成物 |
CN103520397B (zh) * | 2013-10-31 | 2015-04-15 | 刘青云 | 一种治疗毛发红糠疹的中药 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05320036A (ja) * | 1992-05-19 | 1993-12-03 | Shiseido Co Ltd | 一重項酸素除去組成物 |
JP3597245B2 (ja) * | 1995-02-23 | 2004-12-02 | 花王株式会社 | シワ形成抑制剤 |
US5804594A (en) * | 1997-01-22 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
JP3906514B2 (ja) * | 1997-04-03 | 2007-04-18 | 味の素株式会社 | アミノ酸誘導体及び抗活性酸素剤 |
JPH11246396A (ja) * | 1998-02-27 | 1999-09-14 | Shiseido Co Ltd | 免疫賦活剤 |
PT951842E (pt) * | 1999-01-20 | 2003-04-30 | Nutricia Nv | Formula de alimento adaptada para bebe |
JP4520089B2 (ja) * | 2002-05-31 | 2010-08-04 | サントリーホールディングス株式会社 | ルブロフサリン配糖体含有組成物 |
JP4291628B2 (ja) | 2003-06-12 | 2009-07-08 | 株式会社資生堂 | 液体クロマトグラフ装置及び試料に含まれる光学異性体の分析方法 |
WO2005006878A1 (en) * | 2003-07-07 | 2005-01-27 | Hill's Pet Nutrition, Inc. | Compositions for improved oxidative status in companion animals |
US20050090551A1 (en) * | 2003-10-27 | 2005-04-28 | Board Of Trustees Of Southern Illinois University | Therapeutic use of methionine for the treatment or prevention of mucositis |
EP1796635A2 (en) * | 2004-09-14 | 2007-06-20 | Molecular Therapeutics, Inc. | D-methionine formulation with improved biopharmaceutical properties |
JP5061364B2 (ja) * | 2006-03-22 | 2012-10-31 | 塩野香料株式会社 | 新規化合物、抗酸化剤及び化粧料、飲食品 |
BRPI0710212A2 (pt) * | 2006-04-04 | 2011-05-24 | Hills Pet Nutrition Inc | método, composição adequada e kit adequado para melhorar o estado antioxidante de um animal, composição adequada para melhorar o estado antioxidante de um felino, meio para comunicação de informação ou instruções, e, uso de uma composição |
JP4980740B2 (ja) | 2007-01-31 | 2012-07-18 | 株式会社 資生堂 | 2次元液体クロマトグラフィー分析方法および分取用流路切り替えユニット |
KR20120041740A (ko) * | 2009-09-14 | 2012-05-02 | 가부시키가이샤 시세이도 | 자외선 장해 경감 조성물 |
JP2012077022A (ja) * | 2010-09-30 | 2012-04-19 | Shiseido Co Ltd | Il−8発現抑制組成物 |
-
2010
- 2010-03-31 WO PCT/JP2010/055841 patent/WO2011040070A1/ja active Application Filing
- 2010-03-31 TW TW099110035A patent/TW201110995A/zh unknown
- 2010-03-31 US US13/261,161 patent/US20120189563A1/en not_active Abandoned
- 2010-03-31 CN CN2010800366376A patent/CN102481277A/zh active Pending
- 2010-03-31 EP EP10820190.6A patent/EP2484353A4/en not_active Withdrawn
- 2010-03-31 KR KR1020127002368A patent/KR20120044993A/ko not_active Application Discontinuation
- 2010-03-31 JP JP2011534100A patent/JP5703228B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP2484353A1 (en) | 2012-08-08 |
KR20120044993A (ko) | 2012-05-08 |
JPWO2011040070A1 (ja) | 2013-02-21 |
WO2011040070A1 (ja) | 2011-04-07 |
EP2484353A4 (en) | 2013-04-17 |
JP5703228B2 (ja) | 2015-04-15 |
CN102481277A (zh) | 2012-05-30 |
US20120189563A1 (en) | 2012-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5934405B2 (ja) | 紫外線障害軽減組成物 | |
JP5795960B2 (ja) | 紫外線障害軽減組成物 | |
TWI550063B (zh) | Antioxidant composition | |
TW201110995A (en) | Oral composition for alleviation of ultraviolet radiation-induced damage | |
JP2007126399A (ja) | グルタチオン増加用組成物 | |
WO2011040166A1 (ja) | シワ形成軽減経口組成物 | |
WO2012043185A1 (ja) | Il-8発現抑制組成物 | |
JPWO2015015815A1 (ja) | 繊維芽細胞賦活剤 |